1-3 of 3
Michael Z. Koontz
Close
Sort by
Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Aaron D. Goldberg, Felipe Samaniego, Maro Ohanian, Paul B. Koller, Namrata Sonia Chandhok, Ahad A. Sadiq, Daruka Mahadevan, Mohamad A. Cherry, Jessica K. Altman, John M. Burke, Michael Z. Koontz, J. C. C Villasboas, Ben K. Tomlinson, Laura E. Finn, Erin G Reid, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth Heritage Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Eric Tam, Donna Nguyen Haney, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar
Journal: Blood
Blood (2023) 142 (Supplement 1): 5953.
https://doi.org/10.1182/blood-2023-181151
Published: 2023
Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Felipe Samaniego, Ahad A. Sadiq, Daruka Mahadevan, Michael Z. Koontz, Jose C. Villasboas, John M. Burke, Erin G Reid, Mohamad Cherry, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth H. Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar
Journal: Blood
Blood (2022) 140 (Supplement 1): 6498–6500.
https://doi.org/10.1182/blood-2022-163683
Published: 2022
Journal Articles

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Michael Z. Koontz, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Jacalyn Rosenblatt, Julia Prescott, Kelsey Tague, Veronica Romines, Meredith Bertoni, Amada Metivier, Rebekah Medina, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 1649.
https://doi.org/10.1182/blood-2021-149797
Published: 2021